Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study.
Girard N, Guisier F, Swalduz A, Van Hulst S, Pichon E, Lavaud P, Greillier L, Tiotiu A, Madroszyk A, Bylicki O, Canellas A, Belmont L, Zysman M, Hauss PA, Godbert B, Audigier-Valette C, Lebreton C, Morin F, Westeel V. Girard N, et al. Among authors: bylicki o. ESMO Open. 2024 Dec;9(12):103968. doi: 10.1016/j.esmoop.2024.103968. Epub 2024 Nov 27. ESMO Open. 2024. PMID: 39608302 Free PMC article.
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
Léna H, Greillier L, Cropet C, Bylicki O, Monnet I, Audigier-Valette C, Falchero L, Vergnenègre A, Demontrond P, Geier M, Guisier F, Hominal S, Locher C, Corre R, Chouaid C, Ricordel C; GFPC 08–2015 ENERGY investigators. Léna H, et al. Among authors: bylicki o. Lancet Respir Med. 2024 Oct 29:S2213-2600(24)00264-9. doi: 10.1016/S2213-2600(24)00264-9. Online ahead of print. Lancet Respir Med. 2024. PMID: 39486424
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial.
Spicer JD, Garassino MC, Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Arunachalam A, Keller SM, Samkari A, Gao S; KEYNOTE-671 Investigators. Spicer JD, et al. Among authors: bylicki o. Lancet. 2024 Sep 28;404(10459):1240-1252. doi: 10.1016/S0140-6736(24)01756-2. Epub 2024 Sep 14. Lancet. 2024. PMID: 39288781 Clinical Trial.
A prospective analysis of the management practices for patients with Stage-III-N2Non-Small-Cell lung cancer (OBSERVE IIIA-B GFPC 04-2020Study).
Jacob M, Fournel P, Tissot C, Cadranel J, Bylicki O, Monnet I, Justeau G, Ricordel C, Thomas P, Falchero L, Locher C, Wislez M, Vergnenegre A, Abdiche S, Guisier F, Bizieux A, Lamy R, François G, De Chabot G, Pierret T, Sabatini M, Abeillera M, Vieillot S, Martinez S, Morel H, Doubre H, Madroszyk A, Geier M, LucLabourey J, Chouaïd C, Greillier L. Jacob M, et al. Among authors: bylicki o. Lung Cancer. 2024 Aug;194:107868. doi: 10.1016/j.lungcan.2024.107868. Epub 2024 Jul 11. Lung Cancer. 2024. PMID: 39003937 Free article.
Real-World efficacy and safety of combination nivolumab plus ipilimumab for Untreated, Unresectable, pleural Mesothelioma: The Meso-Immune (GFPC 04-2021) trial.
Bylicki O, Guisier F, Scherpereel A, Daniel C, Swalduz A, Grolleau E, Bernardi M, Hominal S, Prevost JB, Pamart G, Marques MH, Cloarec N, Deshayes S, Raimbourg J, Veillon R, Oulkhouir Y, Audigier Valette C, Subtil F, Chouaïd C, Greillier L; GFPC. Bylicki O, et al. Lung Cancer. 2024 Aug;194:107866. doi: 10.1016/j.lungcan.2024.107866. Epub 2024 Jun 29. Lung Cancer. 2024. PMID: 38972083 Free article.
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study).
Amari L, Tomasini P, Dantony E, Rousseau-Bussac G, Ricordel C, Bigay-Game L, Arpin D, Morel H, Veillon R, Justeau G, Huchot E, Fournel P, Vergnenegre A, Bizeux A, Subtil F, Clarisse B, Decroisette C, Chouaid C, Greillier L, Bylicki O. Amari L, et al. Among authors: bylicki o. Lung Cancer. 2024 Jul;193:107843. doi: 10.1016/j.lungcan.2024.107843. Epub 2024 May 31. Lung Cancer. 2024. PMID: 38830303 Free article. Clinical Trial.
Resected EGFR-mutated non-small-cell lung cancers: incidence and outcomes in a European population (GFPC Exerpos Study).
Auliac JB, Thomas PA, Bylicki O, Guisier F, Curcio H, AlainVegnenègre, Swalduz A, Wislez M, Le Treut J, Decroisette C, Basse V, Falchero L, De Chabot G, Moreau D, Huchot E, Lupo Mansuet A, Blons H, Chouaïd C, Greillier L. Auliac JB, et al. Among authors: bylicki o. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241236451. doi: 10.1177/17588359241236451. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 38455711 Free PMC article.
Long-Term Consequences of Spirometry During Military Routine Medical Examinations on Smoking Cessation Compared to Minimal Advice.
Perisse A, Dao MC, Butty D, Derkenne C, Charton F, Fabre N, Grosset-Janin A, Lutringer M, Chanet A, Diop E, Attia C, Coudert A, Courson A, Maillot G, Augen AS, Bagary P, Sahuguet E, Remond O, Paleiron N, Bylicki O. Perisse A, et al. Among authors: bylicki o. Mil Med. 2024 Aug 30;189(9-10):2016-2022. doi: 10.1093/milmed/usad473. Mil Med. 2024. PMID: 38109715 Clinical Trial.
Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer.
Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, Winder T, Zukov R, Garbaos G, Gao S, Kuroda H, Ostoros G, Tran TV, You J, Lee KY, Antonuzzo L, Papai-Szekely Z, Akamatsu H, Biswas B, Spira A, Crawford J, Le HT, Aperghis M, Doherty GJ, Mann H, Fouad TM, Reck M; AEGEAN Investigators. Heymach JV, et al. N Engl J Med. 2023 Nov 2;389(18):1672-1684. doi: 10.1056/NEJMoa2304875. Epub 2023 Oct 23. N Engl J Med. 2023. PMID: 37870974 Clinical Trial.
Venous thrombotic events and impact on outcomes in patients treated with first-line single-agent pembrolizumab in PD-L1 ≥ 50% advanced non small cell lung cancer.
Doubre H, Greillier L, Justeau G, Ricordel C, Swalduz A, Curcio H, Bylicki O, Auliac JB, Guisier F, Bigay-Game L, Bernardi M, Pinsolle J, Amrane K, Decroisette C, Descourt R, Chouaid C, Geier M. Doubre H, et al. Among authors: bylicki o. J Cancer Res Clin Oncol. 2023 Nov;149(16):15095-15102. doi: 10.1007/s00432-023-05321-w. Epub 2023 Aug 25. J Cancer Res Clin Oncol. 2023. PMID: 37626173
67 results